Reportedly, CD73 is a combination therapy target that can improve the anti-GBM immune responses induced by anti-PD-1 immunotherapy [53], and our results demonstrated that the miR-21 inhibitor-Dex complex could inhibit CD73 expression on MDSCs in the glioma microenvironment. This evidence concerns the gene NT5E and central nervous system cancer.